Effectiveness and safety of upadacitinib retreatment after withdrawal in moderate-to-severe atopic dermatitis: a retrospective study
Clinical and Experimental Dermatology · 26.03.2025 · 50 (4) · 770-778
DOI: 10.1093/ced/llae410 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 08.10.2024. Verfasst von Teppei Hagino und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Heterocyclic Compounds, 3-Ring, Dermatologic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Background
Upadacitinib, a Janus kinase 1 (JAK1) inhibitor, is effective for moderate-to-severe atopic dermatitis (AD). Upadacitinib treatment may be discontinued in some patients; however, the effectiveness and safety of retreatment after its withdrawal have not been examined in detail in real-world practice.
Objectives
To evaluate the effectiveness and safety of upadacitinib retreatment after withdrawal in real-world clinical practice for Japanese patients with AD.
Methods
This retrospective study included 62 Japanese patients with moderate-to-severe AD treated with upadacitinib 15 mg (n = 38) or 30 mg (n = 24). Effectiveness was assessed using the Eczema Area and Severity Index (EASI) and Peak Pruritus Numerical Rating Scale (PP-NRS) before treatment (baseline), at timepoints of discontinuation, at retreatment, and at week 12 after retreatment with upadacitinib. Safety was evaluated through the incidence of treatment-emergent adverse events (TEAEs).
Results
EASI and PP-NRS scores significantly decreased at week 12 after upadacitinib retreatment compared with baseline in both the 15-mg and 30-mg groups (P = 0.01 for EASI and PP-NRS in both groups). At week 12 after retreatment, achievement rates of at least a 75%, 90% or 100% reduction in EASI from baseline (EASI 75, EASI 90 or EASI 100, respectively) were 84%, 57% and 19% in the 15-mg group, and 87%, 57% and 17% in the 30-mg group, respectively. TEAEs were mild or moderate, and no serious AEs or deaths were reported.
Conclusions
Retreatment with upadacitinib after withdrawal effectively improved clinical signs and pruritus in patients with AD, with a manageable safety profile, supporting its use for long-term management of AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
- Department of Dermatology, Nippon Medical School, Tokyo, Japan.
- Fujimoto Dermatology Clinic, Funabashi, Japan.
ORCID-Profile: Teppei Hagino, Hidehisa Saeki, Naoko Kanda
Zitieren
APA
Hagino, T., Saeki, H., Fujimoto, E., & Kanda, N. (2025). Effectiveness and safety of upadacitinib retreatment after withdrawal in moderate-to-severe atopic dermatitis: a retrospective study. Clinical and Experimental Dermatology, 50(4), 770-778. https://doi.org/10.1093/ced/llae410
Vancouver
Hagino T, Saeki H, Fujimoto E, Kanda N. Effectiveness and safety of upadacitinib retreatment after withdrawal in moderate-to-severe atopic dermatitis: a retrospective study. Clinical and Experimental Dermatology. 2025;50(4):770-778. doi:10.1093/ced/llae410
BibTeX
@article{Hagino2025,
author = {Hagino, Teppei and Saeki, Hidehisa and Fujimoto, Eita and Kanda, Naoko},
title = {Effectiveness and safety of upadacitinib retreatment after withdrawal in moderate-to-severe atopic dermatitis: a retrospective study},
journal = {Clinical and Experimental Dermatology},
year = {2025},
volume = {50},
number = {4},
pages = {770--778},
doi = {10.1093/ced/llae410}
}
EUVIMED